Health & Fitness
Health and Fitness
Health and Fitness
Tue, March 13, 2012Mon, March 12, 2012Sat, March 10, 2012Fri, March 9, 2012Thu, March 8, 2012Wed, March 7, 2012Tue, March 6, 2012Mon, March 5, 2012Fri, March 2, 2012Thu, March 1, 2012Wed, February 29, 2012TPI Updated Corporate Presentation at 32nd Cowen's Healthcare Conference
Published in Health and Fitness on Tuesday, March 6th 2012 at 11:51 GMT by Market Wire
TPI Updated Corporate Presentation at 32nd Cowen's Healthcare Conference -- CHENGDU, China, March 6, 2012 /PRNewswire-Asia/ --
TPI Updated Corporate Presentation at 32nd Cowen's Healthcare Conference
CHENGDU, China, March 6, 2012 /PRNewswire-Asia/ -- Tianyin Pharmaceutical Inc. (NYSE Amex: [ TPI ]), a pharmaceutical company that specializes in the research, development and sale of patented biopharmaceutical medicine, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) presented and participated in the panel discussion on healthcare reform and pricing at the 32nd Cowen's Healthcare Conference on Monday, March 5th, 2012 at the Boston Marriott Copley Place Hotel. The updated corporate presentation is available via the link: [ http://www.tianyinpharma.com/download/TPI_March_2012.pdf ]
About TPI
Headquartered at Chengdu, China, TPI is a pharmaceutical company that specializes in the development, manufacturing, marketing and sales of patented biopharmaceutical, mTCM, branded generics and API. TPI currently manufactures a comprehensive portfolio of 58 products, 24 of which are listed in the highly selective national medicine reimbursement list, 7 are included in the essential drug list of China. TPI's pipeline targets various high incidence healthcare indications. For more information about TPI, please visit: [ http://www.tianyinpharma.com ]
Safe Harbor Statement
The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.
For more information, please visit: [ http://www.tianyinpharma.com ], or email: [ ir@tpi.asia ]
Tel: +86-28-8551-6696 (Chengdu, China )
+86-134-3655-0011 ( China )
Address:
Tianyin Pharmaceutical Inc.
23rd Floor, Unionsun Yangkuo Plaza
No. 2, Block 3, South Renmin Road
Chengdu , 610041
China
SOURCE Tianyin Pharmaceutical Co., Inc.
[ Back to top ] RELATED LINKS
[ http://www.tianyinpharma.com ]
[ http://www.tianyinpharma.com/download/TPI_March_2012.pdf ]
